IP Library Granted Patent US 8,921,561
Granted Patent B2
US 8,921,561 · App. 13/749,805 · Granted Dec 30, 2014

One-pot preparation of hexahydroisoquinolines from amides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,561
App. No.
13/749,805
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.

Claims (51)

1. A one-pot process for the preparation of a compound having Formula (III′), the process comprising:

(a) contacting a compound having Formula (I) with POCl 3 to form a compound having Formula (II); and

(b) contacting the compound having Formula (II) with an asymmetric catalyst and a hydrogen donor comprising a formate ion to form a compound having Formula (III′)

according to the following reaction scheme:

wherein:

R 1 , R 5 , and R 7 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 111 ;

R 2 , R 4 , and R 6 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 211 ;

R 3 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 211 ;

R 12 and R 13 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 111 ;

R 111 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 211 is chosen from hydrogen, hydrocarbyl, —C(O)R 212 , —O(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ;

R 212 is chosen from hydrocarbyl and substituted hydrocarbyl; and

the compound having Formula (II) is not isolated as a solid prior to step (b).

2. The process of claim 1 , wherein a compound having Formula (III) is also formed during step (b):

wherein:

R 1 , R 5 , and R 7 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 111 ;

R 2 , R 4 , and R 6 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 211 ;

R 3 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and —OR 211 ;

R 12 and R 13 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, and —OR 111 ;

R 111 is chosen from hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 211 is chosen from hydrogen, hydrocarbyl, —C(O)R 212 , —O(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from hydrocarbyl and substituted hydrocarbyl.

3. The process of claim 1 , wherein:

R 3 is —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

4. The process of claim 1 , wherein:

R 4 is —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)O(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

5. The process of claim 1 , wherein:

R 6 is —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)O(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

6. The process of claim 1 , wherein R 1 , R 2 , R 5 , R 7 , R 12 , and R 13 are hydrogen; R 3 and R 6 are methoxy; R 4 is chosen from hydroxyl, —OC(O)CH 3 , —C(O)C(CH 3 ) 3 , —OC(O)Ph, and —OSO 2 CH 3 ; R 12 is chosen from alkyl, allyl, benzyl, and halo; and R 212 is methyl.

7. The process of claim 1 , wherein:

R 3 , R 4 , and R 6 are —OR 211 ;

R 211 is chosen from hydrogen, alkyl, —C(O)R 212 , —C(O)C(R 212 ) 3 , —C(O)NHR 212 , and —SO 2 R 212 ; and

R 212 is chosen from alkyl and aryl.

8. The process of claim 1 , wherein the molar ratio of the compound comprising Formula (I) to POCl 3 is from about 1:0.5 to about 1:5.

9. The process of claim 1 , wherein the asymmetric catalyst comprises a metal or a metal source and a chiral ligand.

10. The process of claim 9 , wherein the metal or metal source is chosen from ruthenium, a ruthenium complex, osmium, an osmium complex, rhodium, a rhodium complex, iridium, an iridium complex, palladium, a palladium complex, platinum, a platinum complex, and combinations thereof; and the chiral ligand is a compound chosen from Formula 670, Formula 680, Formula 690, and Formula 700:

wherein:

R 671 , R 672 , R 673 , R 681 , R 691 , R 692 , R 701 , and R 702 are independently alkyl or aryl; and

R 691 and R 692 of Formula 690 and R 701 and R 702 of Formula 700, and the carbon atoms to which they are attached, may optionally form a cyclic or bicyclic compound.

11. The process of claim 9 , wherein the metal source is dichloro(p-cymene) ruthenium(II) dimer and the chiral ligand is (1S,2S)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine.

12. The process of claim 1 , wherein the weight ratio of the asymmetric catalyst to the compound having Formula (II) is about 0.001:1 to about 0.1:1; the molar ratio of the compound having Formula (II) to the hydrogen donor is about 1:1 to about 1:20.

13. The process of claim 1 , wherein the hydrogen donor is chosen from formic acid, a salt of formic acid, and a mixture of formic acid and an organic base.

14. The process of claim 1 , wherein the hydrogen donor comprises formic acid and triethylamine.

15. The process of claim 2 , wherein steps (a) and (b) are conducted at a temperature from about 20° C. to about 100° C.; and the compound having Formula (III) has a yield of at least about 60%.

16. The process of claim 1 , wherein the molar ratio of the compound having Formula (I) to POCl 3 is about 1:1; the asymmetric catalyst comprises dichloro(p-cymene) ruthenium(II) dimer and either (1S,2S)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine or (1R,2R)-(+)-N-4-tolylsulfonyl-1,2-diphenylethylene-1,2-diamine; the weight ratio of the asymmetric catalyst to the compound having Formula (II) is about 0.01:1; the hydrogen donor comprises formic acid and triethylamine; the molar ratio of the compound having Formula (II) to formic acid to triethylamine is from about 1:4:2 to about 1:6:3; and steps (a) and (b) are conducted at a temperature from about 22° C. to about 25° C.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →